Tustin, CA-based Peregrine Pharmaceuticals says its lead program, bavituximab, has hit its primary endpoint in a Phase II study for advanced breast cancer. Fourteen of the 15 patients enrolled in Stage A were deemed evaluable for tumor response, with seven patients achieving an objective response by approximately eight weeks, after completing two treatment cycles. Six of the patients achieved partial tumor responses and one patient achieved a complete tumor response, according to RECIST criteria. "The results reported today reinforce the positive early data seen in our Phase II breast cancer trial assessing bavituximab in combination with docetaxel, as well as the promising early data we reported last week from our Phase II bavituximab lung cancer trial," said CEO Steven W. King. Peregrine release